EUCTR2016-001521-13-AT进行中（未招募）1 期
A PHASE II TRIAL OF LONG-TERM TREATMENT WITH AZITHROMYCIN IN PATIENTS WITH LYMPHOMA OF THE MUCOSA ASSOCIATED LYMPHOID TISSUE (MALT) LYMPHOMA - MALT-A 1
Med. Univ. Wien0 个研究点目标入组 16 人开始时间: 2016年5月19日最近更新:
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 16
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •- Histologically confirmed MALT lymphoma with measurable disease (stage I – IV)
- •- Gastric lymphoma: First or greater relapse after surgery, radiation, chemotherapy or HP-eradication (patients judged refractory to HP-eradication by a minimum follow-up of 12 months after successful HP-eradication in case of HP-positive gastric lymphoma) or refractoriness/persistence to the said measures. HP-negative patients are directly eligible and no initial attempt with antibiotics is considered in daily practice, as efficacy is low.
- •- Extragastric lymphoma: Measurable disease stage I - IV
- •- Age > 18 years
- •- Life expectancy of at least 3 months
- •- Patient must be able to tolerate therapy, and have adequate cardiac, renal and liver function
- •- ECOG-PS status of ? 3
- •- Patient must be capable of understanding the purpose of the study and have given written informed consent.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 23
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 23
排除标准
- •- Lymphoma histology other than MALT lymphoma or MALT lymphoma with a diffuse large cell lymphoma (high grade lymphoma”) - component
- •- Use of any investigational agent within 28 days prior to initiation of treatment
- •- History of malignancy other than squamous cell carcinoma, basal cell carcinoma of the skin or carcinoma in situ of the cervix within the last 3 years
- •- Major surgery, other than diagnostic surgery, within the last 4 weeks
- •- Evidence of CNS involvement
- •- A history of uncontrolled seizures, central nervous system disorders or psychiatric disability judged by the investigator to be clinically significant and adversely affecting compliance to study drugs
- •- Clinically significant cardiac disease including unstable angina, acute myocardial infarction within six months prior to randomization, congestive heart failure (NYHA III-IV), arrhythmia unless controlled by therapy, with the exception of extra systoles or minor conduction abnormalities, and long QT syndrome (QTc interval >450 ms).
- •- Subjects who have current active hepatic or biliary disease (with exception of patients with Gilbert's syndrome, asymptomatic gallstones, liver metastases or stable chronic liver disease per investigator assessment
- •- Inadequate hematological status at baseline prior to study entry: Dependency on red blood cell and/or platelet transfusions, ANC (absolute neutrophil count (segmented + bands) <1.0 x 109/L; platelets <50 x 109/L
- •- Inadequate kidney function: serum-creatinine >2.0 times upper normal limit
- •- Hepatic dysfunction: total bilirubin >1.5 times upper normal limit (unless due to DLBCL involvement of liver or a known history of Gilbert’s disease); ALT >2.5 times upper normal limit (unless due to disease involvement of liver); alkaline phosphatase >2.5 times upper normal limit (unless due to disease involvement of the liver or bone marrow)
- •- Patients with active opportunistic infections
- •- Known HIV positivity
- •- Pregnant or lactating women. Women of childbearing potential must have a negative pregnancy test at screening, pregnancy testing must be performed within 7 days of administration of IMP. Approved methods of birth control must be used
- •- Women of childbearing potential, including women whose last menstrual period was less than one year prior to screening, unable or unwilling to use adequate contraception from study start to one year after the last dose of protocol therapy. Adequate contraception is defined as hormonal birth control, intrauterine device, double barrier method or total abstinence.
- •- Male subjects unable or unwilling to use adequate contraception methods from study start to one year after the last dose of protocol therapy.
- •- Concurrent medication with ergotamine, theophylline or digitalis.
- •MALT-A 1_Version 1.0 Page 8 of 43
- •- Patients who are hypersensitive to IMP (Azithromycin) or other Macrolide antibiotics.
研究者
相似试验
招募中
3 期
ong-term treatment with azithromycin to prevent bronchiectasis and recurrent cough (LEAP-Cough)Chronic wet coughRespiratory - Other respiratory disorders / diseasesACTRN12623000098639Queensland University of Technology274
进行中（未招募）
不适用
A phase II study of the use of azacitidine for the treatment of patients with chronic graft-versus-host-disease who have failed treatment with corticosteroidsChronic Graft versus Host DiseaseMedDRA version: 18.1Level: PTClassification code 10066261Term: Chronic graft versus host diseaseSystem Organ Class: 10021428 - Immune system disordersEUCTR2014-005659-19-GBniversity of Birmingham
进行中（未招募）
1 期
Phase ll Study of the Adjunctive Use of Azacitidine in Patients Undergoing Reduced Intensity Allogeneic Transplantation for Acute Myeloid Leukaemia - RICAZAEUCTR2007-006475-36-GBniversity of Birmingham40
进行中（未招募）
1 期
ordic multicenter phase II study: Treatment of patients with Acute Myeloid Leukemia (AML) with AZACITIDINE and reduced dose of VENETOCLAX (including laboratory research for improvement of AML treatment).Acute myeloid leukemia (AML)MedDRA version: 21.0Level: LLTClassification code 10000886Term: Acute myeloid leukemiaSystem Organ Class: 100000004864EUCTR2020-005461-14-DKRigshospitalet117
进行中（未招募）
1 期
ordic multicenter phase II study: Treatment of patients with Acute Myeloid Leukemia (AML) with AZACITIDINE and reduced dose of VENETOCLAX (including laboratory research for improvement of AML treatment).Acute myeloid leukemia (AML)MedDRA version: 21.0Level: LLTClassification code 10000886Term: Acute myeloid leukemiaSystem Organ Class: 100000004864EUCTR2020-005461-14-FIRigshospitalet117